Oral Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2024 titled, “AKY-1189, a novel, first-in-class miniprotein radiopharmaceutical designed to deliver Actinium-225 (225Ac) to Nectin-4 expressing tumors with broad therapeutic applications in metastatic urothelial carcinoma (mUC) and other Nectin-4 expressing tumors.”